Introduction
============

Dissemination of carbapenem-resistant organisms continues to cause an increasing number of severe and often untreatable bacterial infections in nosocomial settings ([@B15]). Production of active carbapenemase is a major carbapenem resistance mechanism among clinical Gram-negative isolates. There are several major classes of carbapenemase, including Class A serine carbapenemases such as *Klebsiella pneumoniae* carbapenemase (KPC), Class B metallo-β-lactamase such as New Delhi metallo-β-lactamse (NDM), Verona integron-encoded metallo-β-lactamase (VIM), IMP, and Carbapenem-hydrolyzing Class D β-lactamases (CHDL) such as OXA-48, OXA-23, OXA-24, etc. [@B8]. In addition, OXA-51 has been reported to be intrinsic to *Acinetobacter baumannii* and it normally does not lead to carbapenem resistance unless an Insertion Sequence, IS*Aba1*, is introduced into its upstream region, enhancing the strength of the promoter and causing over-expression of the *oxa-51* gene. Even if this happens, it has been reported that the CHDL OXA-51 produced exhibits only weak carbapenemase activity ([@B12]). Determination of the presence of carbapenemase activity is pivotal for clinicians to devise a suitable treatment regimen. To date, several enzymatic- and inhibitor-based phenotypic assays have been developed for detection of bacterial carbapenemase activities. Enzymatic assays, including Modified Hodge Test (MHT) and Carba NP test, involve the direct observation of carbapenmase hydrolysing phenotype in the presence of an indicator organism or a pH indicator ([@B7]). Inhibitor assays which include commercially available *E* test MBL Strip ([@B6]) and the Imipenem/EDTA inhibition test, deploy chemicals such as EDTA, a metal chelator, to inhibit enzyme activity, and are mainly used for detecting Metallo-β-lactamase (MBL) activity. Above all, MHT is a recommended method for identifying carbapenemase producers ([@B2]). However, this method is not ideal for detection of CHDL, including OXA-51, OXA-23, and OXA-58 in *Acinetobacter* ([@B3]). OXA-51 is intrinsic to *A. baumannii* and normally does not lead to carbapenem resistance, thus it is regarded as a less active carbapenemase, unless it is over-expressed by introduction of a strong promoter in its upstream region as a result of insertion of the insertion sequence IS*Aba1*([@B12]). Detection of other CHDLs such as OXA-23 and OXA-58 in *A. baumannii* has always been a challenge due to the low membrane permeability of the organisms ([@B3]). Failure to detect carbapenemases produced by clinical strains is a serious concern since false categorization of the corresponding resistant organisms may result in wrong diagnosis and ineffective treatment. Although performance of *Pseudomonas aeruginosa* as an indicator strain in MHT to detect MBLs was found to be unsatisfactory previously due to the low specificity of this method and its high tendency to produce intermediate results ([@B9]), the suitability of this test approach to detect CHDLs has not been evaluated. In this work, replacement of *Escherichia coli* ATCC25922 by *P. aeruginosa* PAO1 as the indicator strain was found to significantly improve sensitivity in detection of less active carbapenemase producers. We showed that combined analysis of results of carbapenemase detection tests with MHT and PAO1--MHT, which cover detection sensitivity toward CHDLs and other carbapenemases, as well as those of PCR genotyping of carbapenemase genes, allows highly accurate assessment of the type and relative role of the carbapenemase involved in conferring the observable phenotype. This analytical approach shall therefore help better define the molecular basis of clinical carbapenem resistance and establish a profile of carbapenemase-encoding elements commonly harbored by each of the key Gram-negative pathogens. Such data are essential for future development of novel antimicrobial strategies, especially those involved in carbapenemase inhibition.

Materials and Methods {#s1}
=====================

Bacterial Isolates
------------------

A total of 102 clinical isolates were collected from patients in The Prince of Wales Hospital, Hong Kong (*n* = 27), and Henan Provincial People's Hospital, Henan, China (*n* = 75). The collection comprised *A. baumannii* (*n* = 68), *P. aeruginosa* (*n* = 32), *Enterobacter cloacae* (*n* = 1) and *E. coli* (*n* = 1). Four *P. otitidis* isolates recovered from food products were also included as control (**Table [1](#T1){ref-type="table"}**). The isolates were identified by the Vitek Bacterial Identification System, followed by 16SrRNA sequencing.

###### 

Primers used in this study.

  β-lactamase     Forward sequence (5′--3′)   Reverse sequence (5′--3′)   Amplicon size (bp)   Reference
  --------------- --------------------------- --------------------------- -------------------- -----------
  *bla*~OXA-51~   TAATGCTTTGATCGGCCTTG        TGGATTGCACTTCATCTTGG        353                  [@B14]
  *bla*~OXA-23~   GATCGGATTGGAGAACCAGA        ATTTCTGACCGCATTTCCAT        501                  
  *bla*~OXA-24~   GGTTAGTTGGCCCCCTTAAA        AGTTGAGCGAAAAGGGGATT        246                  
  *bla*~OXA-58~   AAGTATTGGGGCTTGTGCTG        CCCCTCTGCGCTCTACATAC        599                  
                                                                                               
  *bla*~IMP~      GGAATAGAGTGGCTTAAYTCTC      GGTTTAAYAAAACAACCACC        232                  [@B10]
  *bla*~V\ IM~    GATGGTGTTTGGTCGCATA         CGAATGCGCAGCACCAG           390                  
  *bla*~OXA~      GCGTGGTTAAGGATGAACAC        CATCAAGTTCAACCCAACCG        438                  
  *bla*~SIM~      TACAAGGGATTCGGCATCG         TAATGGCCTGTTCCCATGTG        570                  
  *bla*~KPC~      CGTCTAGTTCTGCTGTCTTG        CTTGTCATCCTTGTTAGGCG        798                  
  *bla*~SPM~      AAAATCTGGGTACGCAAACG        ACATTATCCGCTGGAACAGG        271                  
  *bla*~DIM~      GCTTGTCTTCGCTTGCTAACG       CGTTCGGCTGGATTGATTTG        699                  
  *bla*~GIM~      TCGACACACCTTGGTCTGAA        AACTTCCAACTTTGCCATGC        477                  
  *bla*~NDM~      GGTTTGGCGATCTGGTTTTC        CGGAATGGCTCATCACGATC        621                  
                                                                                               
  *bla*~POM~      ACGTCGCTGATGCTCAG           CCTGCGTCATCAGAGACCTC        1143                 [@B11]

Antimicrobial Susceptibility Testing
------------------------------------

Antimicrobial susceptibility assay was performed and interpreted according to the CLSI guidelines ([@B2]). Antimicrobial susceptibility testing was carried out by the agar dilution method with meropenem and imipenem as the test agents. Results were interpreted following the CLSI guidelines ([@B2]). *E. coli* strains ATCC 25922, 35218, and *P. aeruginosa* strain ATCC 27853 were used as quality control.

PCR Detection of Carbapenemase Genes
------------------------------------

Possession of carbapenemase genes by isolates was investigated by PCR as described previously ([@B14]; [@B10]; [@B11]; [@B5]). The PCR assays included detection of *bla*~OXA-23~, *bla*~OXA-24~, *bla*~OXA-51~, *bla*~OXA-58~, *bla*~IMP~, *bla*~V\ IM~, *bla*~OXA~, *bla*~SIM~,*bla*~KPC~,*bla*~SPM~, *bla*~DIM~, *bla*~GIM~, *bla*~NDM~, and *bla*~POM~. Primers used in this study are shown in **Table [1](#T1){ref-type="table"}**. Genomic DNA was obtained by using the Purelink Genomic Mini Kit (Life Technologies). 1 μl of DNA template was added into PCR reaction mix (1X PCR Buffer, 3 mM MgCl~2~, 0.2 mM dNTP, 0.25 μM primer, 1U Takara rTaq). The assays were validated by including a pET15B vector carrying target constructs as positive control, and amplicons were subjected to sequencing.

Two-Tiered Modified Hodge Test
------------------------------

Modified Hodge Test for meropenem was performed on all isolates as described using the *E. coli* strain ATCC25922 and *P. aeruginosa* strain PAO1 as indicator organisms (designated as MHT and MHT-PAO1, respectively), and a *bla*~IMP~-producing *E. coli* strain as positive control. Meropenem susceptibility testing disks were obtained from Oxoid, and Mueller-Hinton Agar (MHA) was obtained from BD. Indicator organisms and test isolates were grown overnight on MHA. Bacterial suspension of indicated organism at 0.5 McFarland Standard was prepared by saline and spread on MHA plates on which meropenem disks (10 μg, Oxoid) were placed at center. Inoculated plates were allowed to dry for 10 min followed by streaking a line of test strains with a 10 μl inoculation loop from the drug disk to the edge of agar plate. Results were recorded after 18 h incubation at 37°C. Production of active carbapenemases was regarded as positive upon observation of "clover-leaf" appearance due to enhanced growth of indicator strain toward the meropenem disk alongside the test strain.

Results and Discussion
======================

A total of 106 strains (102 clinical isolates and four food isolates) were first subjected to antibiotic susceptibility tests. Among the 68 *A. baumannii* isolates tested, 52 were resistant to meropenem and imipenem. The rest of the test strains, including 32 *P. aeruginosa* isolates, four *P. Otitis* isolates, one *Enterobacter cloacae* strain, and one *E. coli* strain, were all carbapenem resistant. PCR genotyping experiments showed that known carbapenemase genes were not detectable in as many as 28 carbapenem resistant *P. aeruginosa* strains. The other four strains were found to contain the *bla*~IMP~ (three strains) and *bla*~KPC~ genes (one strain), respectively. MHT tests were then performed to assess the degree of correlation between existence of carbapenemase genes and the detection of carbapenemase activity, with results indicating that the carbapenemase *bla*~IMP~ was detectable by both MHT tests, yet the *bla*~KPC~ enzyme was detectable by MHT-PAO1 only (**Figure [1](#F1){ref-type="fig"}**). Despite such discrepancy, the four host strains concerned all exhibited high level meropenem resistance (≥32 μg/ml), suggesting that active carbapenemase production might not be the sole basis of carbapenem resistance in these organisms. Likewise, 5 of the 28 *P. aeruginosa* strains which did not harbor any known carbapenemase gene were found to produce a carbapenemase phenotype detectable by MHT--PAO1 only; in addition, another two strains were found to produce an enzyme detectable by both MHT tests (**Figure [1](#F1){ref-type="fig"}**). Although false positives have been described in MHT to detect carbapenemases in *P. aeruginosa* previously, it can not rule out the possibility that other unknown carbapenem resistance mechanisms are present in these seven strains ([@B13]). **Table [2](#T2){ref-type="table"}** summarizes the results of genotyping, MHT tests and antibiotic susceptibility levels of the 106 strains studied in this work. For carbapenem-resistant *P. aeruginosa,* MHT--POA1 can detect 100% (4/4) of know carbapenemase producers and 25% (7/28) of isolates without known carbapenemase genes, while MHT can detect 75% (3/4) of know carbapenemase producers and 7% (2/28) of isolates without known carbapenemase genes.

![**Result of Modified Hodge Test for representative isolates. (A)** Modified Hodge Test (MHT--PAO1 of three *bla*~IMP-~borne *Pseudomonas aeruginosa* strains (left, upper, right) with an *Escherichia coli* strain harboring the *bla*~IMP~ gene as positive control (bottom). **(B)** MHT--PAO1 of three *bla*~OXA-23~-borne *Acinetobacter baumannii* strains (left, upper, right) with an *E. coli* strain harboring the *bla*~IMP~ gene as positive control (bottom). **(C)** MHT (Left) and MHT-PAO1 (right) of a *bla*~POM~-borne*P. otitidis* strain (E1-7). **(D)** MHT (Left) and MHT-PAO1 (right) of a *bla*~OXA-23~--borne *A. baumannii* strain (CP51). Arrows indicate enhanced growth of indicator organism.](fmicb-06-00293-g001){#F1}

###### 

Summary of genotypic and phenotypic characteristics of 106 Gram-negative bacterial isolates tested in this study.

  -----------------------------------------------------------------------------------------------------------------------------------------
  Bacterial species tested (Carbapenemases)   Meropenem MIC(μg/ml)   No. of isolates   No. of positive Modified Hodge Test (MHT)   
  ------------------------------------------- ---------------------- ----------------- ------------------------------------------- --------
  *P. aeruginosa*\                            ≥32\                   3\                3\                                          3\
  *bla*~IMP~\                                 ≥32\                   1\                1\                                          0\
  *bla*~KPC~\                                 16 -- ≥32              28                7                                           2^†^\
  Not Detected                                                                                                                     

  *P. otitidis*\                              16 -- ≥32              4                 4                                           0\
  *bla*~POM~                                                                                                                       

  *Acinetobacter baumannii*\                  \<0.5\                 14^∗^\            0 3\                                        0 0\
  *bla*~OXA-51like~\                          8\                     3\                43\                                         16^†^\
  IS*Aba1*+ *bla*~OXA-51like~\                8 -- ≥32\              49\               1\                                          0\
  *bla*~OXA-51/23like~\                       ≥32\                   1\                1                                           0
  *bla*~OXA-51/24like~\                       ≥32\                   1                                                             
  *bla*~OXA-51like~ + *bla*~NDM~\                                                                                                  

  *Enterobacter cloacae*\                     16                     1                 1                                           1
  *bla*~NDM~ + *bla*~KPC~                                                                                                          

  *E. coli*\                                  16                     1                 1                                           0
  *bla*~NDM~                                                                                                                       

                                                                                                                                   

  Total                                                              106               63                                          22
  -----------------------------------------------------------------------------------------------------------------------------------------

Of the 68 *A. baumannii* isolates tested, 17 were found to contain the intrinsic *bla*~OXA-51~-like CHDL-producing gene only, among which were the 14 carbapenem-sensitive strains. Interestingly, the IS*Aba1* element was detectable in the upstream region of a*bla*~OXA-51~-like gene in the other three of these 17 strains, which were also found to produce a carbapenemase detectable only by MHT--PAO1, corroborating with the fact that the IS*Aba1* element is essential for over-expression of the*bla*~OXA-51~-like gene. The remaining 51 isolates were found to harbor other carbapenemase-producing genetic elements, with the vast majority (49 strains) containing the *bla*~OXA-51/23~-like gene. Among these 49 strains, whose meropenem MIC ranged from 8 to ≥32 μg/ml, 16 were positive in both MHT tests, 27 were positive in the MHT-PAO1 only, and six strains did not produce any detectable carbapenemases (**Figure [1](#F1){ref-type="fig"}**). These findings appear to suggest that*bla*~OXA-51/23~-like gene product may not be the sole factor responsible for the development of the carbapenem resistance phenotypes of the organisms concerned.

The other two of the 51 isolates which harbored carbapenemase genes included one highly resistant strain (meropenem MIC ≥ 32 μg/ml) which contained a *bla*~OXA-51/24~-like element. However, this strain was tested positive only in MHT-PAO1, again suggesting the involvement of non-carbapenemase mechanisms. Likewise, another strain which contained both the *bla*~OXA-51~-like and *bla*~NDM~ genes, exhibited a meropenem MIC of ≥32 μg/ml, which is significantly higher than that observed in the three strains containing the*bla*~OXA-51~-like gene alone, plus an IS*Aba1* element (8 μg/ml). Such discrepancy highlighted the additive effects of different enzymes on the strength of phenotypic carbapenem resistance. It should be noted that the phenomenon of high level carbapenem resistance and low level enzyme production was also observable in a meropenem-resistant *E. coli* strain harboring the *bla*~NDM~ gene in this study, as well as several *E. coli* and *K. pneumoniae* isolates described previously ([@B4]). This phenomenon suggests the possibility that the level of carbapenem resistance exhibited by a given clinical isolate is more closely related to the type rather than level of carbapenemase produced by the organism. Alternatively, these findings could also indicate that the *bla*~NDM~ enzyme might only confer relatively low level carbapenem resistance, and other factors including altered membrane permeability and expression of eﬄux may be responsible for the high level carbapenem resistance phenotypes exhibited by the host strains concerned. This possibility is also raised by the finding that the meropenem MIC of an *Enterobacter cloacae* strain, which harbored the *bla*~NDM~ and *bla*~KPC~ genes and exhibited a positive result in both MHT tests, was only16 μg/ml. On the other hand, *bla*~POM~, encoding an intrinsic Metallo-β-Lactamase, was detected in all the four *P. otitidis* isolates (**Table [2](#T2){ref-type="table"}**). This enzyme, which was consistently detectable by the MHT--PAO1 test only, was associated with a meropenem MIC of 16--≥32 μg/ml. These findings suggest a need to investigate the role of each specific carbapenemase in conferring carbapenem resistance in the host strain. In summary, within 60 isolates of carbapenem-resistant *P. otitidis, h coli,* and *K. pneumonia,* 90% (54/60) were positive for MHT--POA1 test, while only 26% (16/60) were positive for MHT testing.

In this work, MHT--PAO1 yielded 63 carbapenemase-positive cases whereas MHT yielded 22 positive cases, with MHT--PAO1 being much more sensitive in detecting CHDL in *A. baumannii*, as well as the *bla*~NDM~ enzyme~.~ Detection of CHDLs produced by *Acinetobacter* by MHT has always been a challenge due to the relative weak activity of enzymes and low membrane permeability of the organism. Unsatisfactory CHDL detection by MHT, including those produced by *bla*~OXA-23~, *bla*~OXA-24,~ and *bla*~OXA-58~, has been documented ([@B1]). Previous studies have also shown that false negative results of MHT in detection of *bla*~NDM~ in *Acinetobacter* and *Enterobacteriaceae* were not uncommon, which may be due to the variation in zinc content in MHA produced by different suppliers ([@B9]; [@B4]). Although performance of *P. aeruginosa* ATCC27853 as indicator strain in MHT to detect certain *P. aeruginosa* MBLs has been attempted by another group which reported a low sensitivity and specificity ([@B9]), our data confirmed that the use of MHT--PAO1 can successfully identify the enzymes encoded by *bla*~IMP~, *bla*~NDM~*~,~* and *bla*~POM~ in *P. aeruginosa*, *E. coli*, and *P. otitidis*, respectively. Currently, testing carbapenemase activity by MHT or other assays has been widely used to determine the carbapenem resistance potential of clinical Gram-negative bacterial pathogens to guide the treatment decision. False negative detection of CHDLs by traditional MHT may result in wrong diagnosis and ineffective treatment. The improved two-tiered MHT can achieve much less false negative, around 9% (6/64) in isolates carrying known carbapenemase genes compared to 71% (45/64) by MHT test, suggesting the high reliability of the two-tiered MHT in the clinical screening of carbapenem-resistant Gram-negative pathogens in particular CHDL producers. If the discrepancy in results of conventional MHT and MHT--PAO1 observable in this study is indeed due to the low enzyme levels as discussed above, future research efforts should be focused on investigating the underlying basis of high level carbapenem resistance in organisms producing less active carbapenemase.

Findings of this study allow us to systematically categorize the test strains according to their carbapenem susceptibility phenotypes and results of the MHT and genotyping tests. As shown in **Table [3](#T3){ref-type="table"}** which lists the scenarios which give rise to at least six possible combinations of the phenotypic and genotypic test results, we can not only better define the relative role of each carbapenemase in the production of a resistance phenotype on the basis of the test results, but also identify strains whose resistance phenotypes were also due to other resistance mechanisms. For example, if a highly resistant strain with positive genotyping result is found to produce a weakly detected carbapenamase (positive in MHT--PAO1 test), it is likely that the resistance phenotype is due to multiple mechanisms including production of active carbapenemase. Here we showed that 34% of the clinical carbapenem resistant *P. aeruginosa* strains tested were at least partially due to carbapenemase, yet the corresponding rate for *A. baumannii* was as high as 89%. Detailed delineation of the molecular basis of carbapenem resistance in these Gram-negative pathogens, which were previously not possible to perform on the basis of a single phenotypic or molecular test, shall greatly facilitate development of novel strategies to treat bacterial infections, especially those aimed at devising a carbapenemase inhibition approach.

###### 

Categorization of carbapenem susceptibility phenotypes.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Category   Carbapenem susceptibility phenotypes   MHT\          MHT-PAO1   PCR-genotyping   Implication                                                                                                                        Examples
                                                    (*E. coli*)                                                                                                                                                                  
  ---------- -------------------------------------- ------------- ---------- ---------------- ---------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  I          S                                      --            --         \+               The carbapenemase gene detectable by genotyping does not produce carbapenemase                                                     14 carbapenem sensitive *A. baumannii* strains harboring the *bla*~OXA-51~ like gene

  II         R                                      --            --         --               Carbapenem resistance not due to carbapenemase                                                                                     21 carbapenem resistant *P. aeruginosa* strains

  III        R                                      +/--          \+         --               Carbapenem resistance due to a combination of resistance mechanisms including an unknown carbapenemase or overexpression of AmpC   Seven *P. aeruginosa* strains

  IV         R                                      \+            \+         \+               Carbapenem resistance due to carbapenemase encoded by the gene detectable by genotyping                                            Various *P. aeruginosa* and *A. baumannii* strains

  V          R                                      --            \+         \+               Carbapenem resistance due to a combination of resistance mechanisms including a weakly detected carbapenemase                      *P. otitidis* and *A. baumannii* strains with a meropenem MIC ≥32 μg/ml

  VI         I                                      --            \+         \+               Carbapenem resistance due to a weakly detected carbapenemase encoded by the gene detectable by genotyping                          Three*A. baumannii* strains harboring the IS*Aba1+ bla*~OXA-51like~ elements
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Categorization according to results of the two-tiered MHT tests and genotyping of carbapenemase genes. S, carbapenem sensitive; R, carbapenem resistant; I, intermediate or low level carbapenem resistance.

Conclusion
==========

A two-tiered MHT approach which conferred two levels of sensitivities for carbapenemase detection can be applied alongside PCR genotyping of known carbapenemase genes to determine the degree of contribution of specific carbapenemase in expression of phenotypic carbapenem resistance in Gram-negative bacterial pathogens. This analytical approach therefore facilitates categorization of carbapenem resistance phenotypes and identification of the major mechanisms concerned in bacterial species in which clinical carbapenem resistance is common.
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